Table of Contents
Ipamorelin - All you need to know
What is Ipamorelin Peptide?
Ipamorelin is a synthetic growth hormone secretagogue (GHS) that has been developed for research into growth hormone regulation and pituitary function. Unlike growth hormone itself, Ipamorelin does not directly supply growth hormone to the body. Instead, it is designed to stimulate the pituitary gland to release the body’s own endogenous growth hormone by activating the ghrelin (growth hormone secretagogue) receptor, also known as the GHS-R1a receptor.
First developed during research into selective growth hormone-releasing compounds, Ipamorelin has attracted considerable scientific interest because of its high receptor selectivity. Compared with earlier growth hormone secretagogues such as GHRP-2 and GHRP-6, laboratory studies suggest that Ipamorelin produces a more selective release of growth hormone while having relatively little effect on other pituitary hormones such as cortisol and prolactin.
Researchers have investigated Ipamorelin in a variety of areas including:
- Growth hormone secretion
- IGF-1 production
- Muscle physiology
- Body composition
- Recovery from exercise
- Sleep physiology
- Healthy ageing
- Bone metabolism
- Tissue repair
- Metabolic health
Unlike Growth Hormone Releasing Hormone (GHRH) analogues such as CJC-1295, which stimulate the pituitary through the GHRH receptor, Ipamorelin works through the ghrelin receptor pathway. Because these two pathways are complementary, researchers frequently investigate Ipamorelin alongside compounds such as CJC-1295 (No DAC) to study whether simultaneous activation of both signalling pathways produces a larger physiological growth hormone pulse than either compound alone.
One of the reasons Ipamorelin has become one of the most widely researched growth hormone secretagogues is its relatively selective mechanism of action. Earlier compounds in this class were often associated with greater stimulation of cortisol, prolactin and appetite. Experimental evidence suggests Ipamorelin produces considerably less activation of these pathways while maintaining robust stimulation of pulsatile growth hormone release.
Growth hormone released following Ipamorelin administration subsequently stimulates the production of Insulin-like Growth Factor-1 (IGF-1), primarily within the liver. Growth hormone and IGF-1 work together to regulate numerous physiological processes including:
- Protein synthesis
- Muscle maintenance
- Connective tissue repair
- Bone remodelling
- Fat metabolism
- Cellular growth
- Recovery from physical stress
Because Ipamorelin stimulates the body’s own pulsatile release of growth hormone rather than continuously elevating circulating hormone levels, researchers believe its physiological profile may more closely resemble natural growth hormone secretion.
Current research is exploring Ipamorelin’s potential role in:
- Age-related decline in growth hormone
- Sarcopenia (loss of muscle mass)
- Exercise recovery
- Body composition
- Metabolic regulation
- Bone health
- Tissue regeneration
- Sleep quality
- Healthy ageing
Despite encouraging laboratory findings, Ipamorelin is not approved as a medicine by the MHRA, EMA or FDA. Most published evidence consists of preclinical research together with a limited number of early human studies. Larger clinical trials are required to establish its long-term safety, optimal dosing strategies and evidence-based therapeutic applications.
How much Ipamorelin should i take?
Published research investigating Ipamorelin has used a variety of experimental protocols, with administration frequency, treatment duration and exposure levels differing between studies. As a result, there is currently no universally accepted or regulator-approved research protocol.
Some laboratory protocols utilise a gradual titration approach, beginning with lower exposure levels before progressively increasing to a maintenance phase. This strategy is commonly used in research to assess tolerability and allow physiological adaptation before higher exposure levels are introduced.
An example laboratory protocol may follow the schedule below:
Dosage Chart
| Tier | Dosage | Frequency | Notes |
|---|---|---|---|
| Weeks 1-2 | 100mcg | Once Daily | ideally 30–60 minutes before bedtime on an empty stomach to synergise with natural nocturnal GH secretion |
| Weeks 3-4 | 150mcg | Once Daily | ideally 30–60 minutes before bedtime on an empty stomach to synergise with natural nocturnal GH secretion |
| Weeks 5-8 | 200mcg | Once Daily | ideally 30–60 minutes before bedtime on an empty stomach to synergise with natural nocturnal GH secretion |
| Weeks 9-12 | 250mcg | Once Daily | ideally 30–60 minutes before bedtime on an empty stomach to synergise with natural nocturnal GH secretion |
Ipamoreln Peptide Benefits
Ipamorelin is one of the most extensively researched growth hormone secretagogues (GHSs). Unlike recombinant growth hormone, which directly increases circulating growth hormone levels, Ipamorelin stimulates the body’s own pituitary gland to release endogenous growth hormone through activation of the ghrelin (GHS-R1a) receptor.
Its high receptor selectivity has made it an important area of investigation within endocrinology, exercise physiology and healthy ageing research. Compared with earlier growth hormone secretagogues, Ipamorelin has demonstrated a more selective growth hormone response with relatively little stimulation of cortisol or prolactin in experimental studies.
Although the available evidence is encouraging, Ipamorelin remains an investigational peptide. Most published research consists of laboratory studies, animal models and early human trials, and further clinical research is required to establish its long-term safety and therapeutic applications.
Current areas of scientific investigation include:
- Growth hormone secretion
- IGF-1 production
- Lean muscle maintenance
- Fat metabolism
- Exercise recovery
- Sleep quality
- Bone metabolism
- Healthy ageing
- Tissue repair
- Metabolic health
Increased Growth Hormone Release
Ipamorelin’s primary mechanism is the stimulation of pulsatile growth hormone release from the anterior pituitary gland.
Unlike synthetic growth hormone, Ipamorelin encourages the body to produce its own endogenous growth hormone, allowing researchers to investigate a physiological pattern of hormone release.
Experimental studies have demonstrated significant increases in circulating growth hormone following administration, making this one of the peptide’s best-established biological effects.
Increased IGF-1 Production
Growth hormone released following Ipamorelin administration stimulates the liver and other tissues to produce Insulin-like Growth Factor-1 (IGF-1).
IGF-1 plays an important role in numerous biological processes including:
- Protein synthesis
- Muscle maintenance
- Bone remodelling
- Connective tissue repair
- Cellular growth
- Recovery from physical stress
Researchers often measure IGF-1 concentrations as a secondary endpoint when investigating growth hormone secretagogues.
Lean Muscle Maintenance
Growth hormone and IGF-1 are closely involved in maintaining lean body mass.
Research has investigated whether Ipamorelin-induced increases in endogenous growth hormone may support:
- Muscle protein synthesis
- Preservation of lean tissue
- Recovery following resistance exercise
- Age-related muscle maintenance
Although these mechanisms are biologically plausible, improvements in muscle mass remain dependent on factors such as resistance training, adequate nutrition and total protein intake.
Fat Metabolism
Growth hormone plays an important role in regulating fat metabolism.
Experimental research has explored whether Ipamorelin may influence:
- Lipolysis (fat breakdown)
- Fat utilisation
- Body composition
- Energy metabolism
Researchers believe these effects are mediated through physiological increases in endogenous growth hormone rather than a direct fat-burning action of the peptide itself.
Exercise Recovery
One of the most common areas of Ipamorelin research involves recovery following physical training.
Growth hormone is involved in normal tissue maintenance and repair, leading researchers to investigate whether increased endogenous growth hormone release may support:
- Recovery from resistance training
- Connective tissue maintenance
- Muscle repair
- Adaptation to exercise
Current evidence remains limited, and further human clinical trials are required.
Sleep Physiology
The majority of natural growth hormone secretion occurs during deep sleep.
Researchers have therefore investigated whether stimulating physiological growth hormone release through Ipamorelin may influence normal sleep-related endocrine activity.
Sleep quality continues to be explored as an outcome measure in growth hormone secretagogue research, although evidence remains limited.
Healthy Ageing
Natural growth hormone secretion gradually declines with age.
This reduction has been associated with changes in:
- Lean muscle mass
- Body composition
- Bone density
- Recovery capacity
- Physical performance
Researchers have investigated whether selective stimulation of endogenous growth hormone may help maintain healthier endocrine function during ageing.
However, Ipamorelin has not been proven to slow or reverse human ageing, and should not be regarded as an approved anti-ageing therapy.
Bone Health
Growth hormone and IGF-1 contribute to normal bone remodelling throughout life.
Experimental research has explored potential effects on:
- Bone turnover
- Bone mineral density
- Osteoblast activity
- Skeletal maintenance
These remain active areas of investigation, particularly in relation to age-related bone loss.
Tissue Repair
Growth hormone and IGF-1 participate in normal tissue maintenance.
Researchers have investigated whether Ipamorelin-induced increases in endogenous growth hormone may influence:
- Connective tissue physiology
- Tendon biology
- Ligament repair
- Muscle recovery
- General tissue remodelling
Current evidence is largely preclinical, and additional human studies are required before definitive conclusions can be drawn.
Improved Selectivity
One of the major advantages of Ipamorelin compared with earlier growth hormone secretagogues is its receptor selectivity.
Experimental studies suggest Ipamorelin stimulates growth hormone release with minimal effects on cortisol, prolactin and appetite compared with compounds such as GHRP-2 and GHRP-6.
This selective pharmacological profile has made Ipamorelin one of the most widely researched peptides within the growth hormone secretagogue class.
Overall Research Summary
Current evidence suggests Ipamorelin may support numerous biological processes associated with physiological growth hormone release, including:
- Increased endogenous growth hormone secretion
- Increased IGF-1 production
- Lean muscle maintenance
- Fat metabolism
- Exercise recovery
- Sleep physiology
- Bone metabolism
- Tissue repair
- Healthy ageing research
- Metabolic regulation
What does Ipamorelin Peptide do?
How This Works
Ipamorelin works by stimulating the body’s natural release of growth hormone rather than supplying growth hormone directly. It belongs to a class of compounds known as growth hormone secretagogues (GHSs) and acts by selectively activating the growth hormone secretagogue receptor (GHS-R1a), commonly referred to as the ghrelin receptor.
Once this receptor is activated, the anterior pituitary gland releases a physiological pulse of endogenous growth hormone. This growth hormone then stimulates the production of Insulin-like Growth Factor-1 (IGF-1), which is responsible for many of the downstream biological effects associated with growth hormone signalling.
Unlike recombinant human growth hormone (HGH), Ipamorelin relies on the body’s own endocrine system and therefore produces a more natural pattern of hormone release.
Ghrelin Receptor Activation
The primary mechanism of Ipamorelin begins with activation of the GHS-R1a receptor.
This receptor is found predominantly within the:
- Pituitary gland
- Hypothalamus
- Central nervous system
It is the same receptor activated by ghrelin, often referred to as the body’s “hunger hormone.”
However, while ghrelin stimulates both appetite and growth hormone release, laboratory studies suggest Ipamorelin has been designed to selectively stimulate growth hormone secretion with minimal effects on appetite compared with earlier growth hormone secretagogues.
Activation of this receptor signals the pituitary gland to release endogenous growth hormone into circulation.
Pulsatile Growth Hormone Release
Growth hormone is naturally released in short pulses throughout the day, with the largest pulses typically occurring during deep sleep.
Rather than maintaining continuously elevated hormone levels, Ipamorelin stimulates the pituitary to produce one of these physiological growth hormone pulses.
Researchers believe this more closely mimics normal endocrine physiology than continuously administering exogenous growth hormone.
Because the pituitary remains under normal hypothalamic feedback control, growth hormone release continues to respond to the body’s own regulatory mechanisms.
Increased IGF-1 Production
Once growth hormone enters the bloodstream, it stimulates the liver and other tissues to produce Insulin-like Growth Factor-1 (IGF-1).
IGF-1 is responsible for many of the biological effects associated with growth hormone and plays important roles in:
- Protein synthesis
- Muscle maintenance
- Bone remodelling
- Connective tissue repair
- Cellular growth
- Recovery following physical stress
Researchers commonly measure circulating IGF-1 concentrations when evaluating the biological activity of Ipamorelin.
Selective Growth Hormone Secretion
One characteristic that distinguishes Ipamorelin from earlier growth hormone secretagogues is its high receptor selectivity.
Compounds such as GHRP-2 and GHRP-6 may stimulate additional pituitary hormones including:
- Cortisol
- Prolactin
and, in some cases, produce a more noticeable increase in appetite.
Experimental studies suggest Ipamorelin stimulates growth hormone release while having relatively little effect on these other hormonal pathways.
This selective pharmacological profile is one of the primary reasons Ipamorelin has become one of the most widely researched peptides in its class.
Synergy with GHRH
Growth hormone secretion is regulated through two complementary pathways.
The first involves Growth Hormone Releasing Hormone (GHRH) acting on the pituitary gland.
The second involves activation of the ghrelin receptor by compounds such as Ipamorelin.
Because these pathways work together physiologically, researchers frequently investigate Ipamorelin alongside GHRH analogues such as CJC-1295 (No DAC).
Simultaneous activation of both pathways has been shown in experimental studies to produce a larger growth hormone pulse than either pathway alone.
This complementary mechanism explains why the CJC-1295 and Ipamorelin combination has become one of the most commonly studied growth hormone peptide protocols.
Natural Endocrine Feedback
Unlike exogenous growth hormone administration, Ipamorelin depends upon a functioning pituitary gland.
Growth hormone secretion remains regulated by the body’s normal feedback systems, including:
- Somatostatin
- Growth Hormone Releasing Hormone (GHRH)
- Circulating IGF-1
As IGF-1 concentrations rise, negative feedback helps reduce further growth hormone release, preventing continuous stimulation of the endocrine system.
This physiological regulation is one reason researchers have investigated growth hormone secretagogues as an alternative approach to directly administering growth hormone.
Protein Synthesis and Tissue Maintenance
Growth hormone and IGF-1 influence several biological processes involved in tissue maintenance.
Experimental research has investigated effects on:
- Muscle protein synthesis
- Connective tissue turnover
- Bone remodelling
- Collagen production
- Cellular repair
These downstream effects occur primarily through growth hormone-induced increases in IGF-1 rather than through direct actions of Ipamorelin itself.
Fat Metabolism
Growth hormone plays an important role in regulating energy metabolism.
Increased endogenous growth hormone release has been associated with:
- Increased lipolysis (fat breakdown)
- Greater utilisation of fatty acids for energy
- Changes in body composition
- Reduced fat storage under certain physiological conditions
Researchers believe these effects result from normal growth hormone physiology rather than any direct fat-burning action of Ipamorelin.
Sleep Physiology
A significant proportion of natural growth hormone secretion occurs shortly after falling asleep during deep slow-wave sleep.
Researchers have investigated whether stimulating physiological growth hormone release with Ipamorelin may complement the body’s normal nocturnal hormone rhythm.
Although sleep quality itself remains an area of ongoing investigation, understanding this natural endocrine rhythm has influenced many experimental research protocols involving growth hormone secretagogues.
Overall Mechanism
Current evidence suggests Ipamorelin functions by selectively stimulating the body’s natural growth hormone axis rather than replacing growth hormone directly.
Its proposed biological actions include:
- Activation of the ghrelin (GHS-R1a) receptor
- Pulsatile endogenous growth hormone release
- Increased IGF-1 production
- Physiological endocrine signalling
- Selective pituitary stimulation
- Support of protein synthesis
- Fat metabolism regulation
- Tissue maintenance and repair
- Synergistic activity with GHRH analogues such as CJC-1295
Ipamorelin Side Effects
Although Ipamorelin has demonstrated a favourable safety profile in early research, it remains an investigational peptide, and long-term safety has not yet been established through large-scale human clinical trials.
Compared with earlier growth hormone secretagogues, Ipamorelin appears to produce a more selective release of growth hormone with relatively little stimulation of cortisol, prolactin or appetite. Nevertheless, any compound that influences the growth hormone/IGF-1 axis has the potential to produce physiological effects that require careful investigation.
Injection Site Reactions
Where Ipamorelin is administered by injection, local reactions may occur.
Potential reactions include:
- Pain or tenderness
- Mild redness
- Swelling
- Bruising
- Temporary itching
- Local irritation
These effects are commonly associated with injectable peptides and are often related to injection technique rather than the peptide itself.
Headache
Some individuals participating in research have reported mild headaches following growth hormone secretagogue administration.
Potential contributing factors include:
- Hormonal fluctuations
- Individual sensitivity
- Changes in fluid balance
- Injection timing
These symptoms are generally temporary and self-limiting.
Water Retention
Growth hormone influences fluid regulation throughout the body.
As endogenous growth hormone and IGF-1 levels increase, some individuals may experience temporary:
- Water retention
- Mild swelling
- A feeling of fullness
- Slight increases in body weight due to fluid retention
These effects are generally more common at higher levels of growth hormone activity.
Temporary Fatigue
Some researchers have reported temporary tiredness or lethargy following administration.
Although the exact mechanism remains unclear, it may reflect short-term endocrine adaptation as growth hormone secretion increases.
Symptoms, where reported, are generally mild and transient.
Dizziness
Occasional dizziness has been reported during studies involving growth hormone secretagogues.
Possible contributing factors include:
- Hormonal changes
- Blood pressure fluctuations
- Individual sensitivity
Researchers should monitor any unexpected symptoms during experimental protocols.
Alterations in Blood Glucose
Growth hormone plays an important role in glucose metabolism.
As a result, compounds that stimulate endogenous growth hormone release may influence:
- Blood glucose regulation
- Insulin sensitivity
- Carbohydrate metabolism
Current evidence suggests Ipamorelin produces smaller metabolic effects than direct growth hormone administration, but further clinical research is required.
Researchers investigating metabolic outcomes should routinely monitor blood glucose where appropriate.
Increased IGF-1
Ipamorelin stimulates endogenous growth hormone release, which subsequently increases circulating Insulin-like Growth Factor-1 (IGF-1).
Although this forms part of its intended biological mechanism, prolonged elevations in IGF-1 remain an important area of ongoing research.
Researchers commonly monitor IGF-1 concentrations throughout studies to evaluate endocrine responses and maintain consistent experimental conditions.
Allergic or Hypersensitivity Reactions
Although uncommon, allergic reactions remain possible with any peptide.
Potential symptoms include:
- Rash
- Itching
- Hives
- Swelling
- Difficulty breathing
Researchers should also consider the possibility of reactions to manufacturing impurities, preservatives or reconstitution diluents rather than the peptide itself.
Infection Risk
Any injectable compound carries a risk of infection if appropriate sterile technique is not followed.
Potential causes include:
- Poor aseptic technique
- Contaminated equipment
- Non-sterile diluent
- Improper storage after reconstitution
Symptoms requiring prompt medical assessment may include:
- Increasing redness
- Swelling
- Heat
- Pus formation
- Fever
- Severe pain
Maintaining strict laboratory handling procedures is essential.
Product Quality
The safety of any research peptide depends heavily on manufacturing quality.
Potential risks associated with poor-quality products include:
- Incorrect peptide identity
- Low purity
- Manufacturing impurities
- Bacterial contamination
- Endotoxins
- Incorrect peptide concentration
- Peptide degradation
Researchers should prioritise products that include:
- Third-party laboratory testing
- Batch-specific Certificates of Analysis (COAs)
- HPLC purity analysis
- Mass spectrometry identity confirmation
These measures improve confidence in product quality but do not replace regulatory approval.
Pregnancy and Breastfeeding
There are currently no adequate human studies evaluating the safety of Ipamorelin during pregnancy or breastfeeding.
Its effects on:
- Fetal development
- Infant exposure
- Reproductive health
remain unknown.
These populations have not been adequately studied.
Unknown Long-Term Safety
Although early studies suggest Ipamorelin is generally well tolerated, long-term human safety data remain limited.
Further clinical research is needed to establish:
- Long-term endocrine effects
- Optimal treatment duration
- Cardiovascular safety
- Metabolic safety
- Reproductive safety
- Drug interactions
Ipamorelin Lifestyle Factors
Lifestyle plays an important role in the function of the growth hormone (GH) and insulin-like growth factor-1 (IGF-1) axis, which Ipamorelin is designed to stimulate. Factors such as sleep, exercise, nutrition and body composition can all influence natural growth hormone secretion and may significantly affect research outcomes.
Researchers investigating Ipamorelin should carefully control these variables to improve study consistency and accurately interpret biological responses.
Sleep
Sleep is one of the strongest natural stimulators of growth hormone release.
The majority of endogenous growth hormone is secreted during the first period of deep slow-wave sleep, making adequate sleep duration and quality essential for maintaining normal endocrine function.
Poor sleep has been associated with:
- Reduced natural growth hormone secretion
- Impaired recovery
- Reduced muscle protein synthesis
- Increased fatigue
- Poor metabolic health
Maintaining a consistent sleep routine is therefore an important consideration in studies investigating growth hormone secretagogues.
Regular Exercise
Exercise naturally stimulates growth hormone release, particularly:
- Resistance training
- High-intensity interval training (HIIT)
- Sprint training
- Vigorous cardiovascular exercise
Regular physical activity also supports:
- Muscle maintenance
- Bone health
- Metabolic function
- Body composition
- Recovery
Researchers should standardise training frequency and intensity wherever possible, as exercise alone can significantly influence growth hormone and IGF-1 levels.
Nutrition
Adequate nutrition is essential for maintaining a healthy endocrine environment.
Particular attention should be given to:
- Total protein intake
- Overall calorie intake
- Micronutrient status
- Hydration
Protein provides the amino acids required for normal tissue maintenance and recovery, while prolonged calorie restriction may suppress natural growth hormone and IGF-1 activity.
A balanced diet supports normal metabolic function and should form the foundation of any research protocol.
Healthy Body Composition
Body composition has a significant influence on growth hormone physiology.
Higher levels of body fat, particularly visceral fat, have been associated with:
- Reduced natural growth hormone secretion
- Lower IGF-1 activity
- Reduced insulin sensitivity
- Metabolic dysfunction
Maintaining a healthy body composition through regular exercise and balanced nutrition may support healthier endocrine function independently of any peptide intervention.
Recovery
Recovery is an essential component of muscle adaptation and hormonal regulation.
Researchers should consider factors including:
- Rest days
- Training volume
- Muscle soreness
- Sleep quality
- Nutritional recovery
Insufficient recovery may impair natural growth hormone secretion and reduce the body’s ability to adapt to exercise.
Stress Management
Chronic psychological stress can negatively affect hormone balance.
Persistently elevated cortisol levels may interfere with:
- Growth hormone secretion
- Sleep quality
- Recovery
- Muscle maintenance
- Metabolic health
Managing stress through healthy lifestyle habits may help maintain normal endocrine function and improve consistency in research outcomes.
Hydration
Adequate hydration supports numerous physiological processes including:
- Nutrient transport
- Cellular metabolism
- Exercise performance
- Recovery
- Temperature regulation
Although hydration does not directly increase growth hormone secretion, dehydration may reduce physical performance and negatively affect recovery.
Alcohol Consumption
Excessive alcohol intake has been shown to impair normal growth hormone secretion and recovery.
Heavy alcohol consumption may contribute to:
- Reduced sleep quality
- Impaired muscle recovery
- Hormonal disruption
- Reduced exercise performance
Limiting alcohol intake supports healthier endocrine function and more consistent research outcomes.
Smoking
Smoking has been associated with increased oxidative stress and impaired recovery.
Long-term smoking may negatively affect:
- Hormonal balance
- Cardiovascular health
- Exercise capacity
- Tissue repair
Avoiding smoking supports overall health and may reduce confounding factors in endocrine research.
Micronutrient Status
Normal hormone production and tissue repair rely on adequate intake of essential vitamins and minerals.
Researchers should ensure sufficient intake of nutrients involved in endocrine and metabolic function, including:
- Vitamin D
- Magnesium
- Zinc
- Vitamin B6
- Calcium
Deficiencies in these nutrients may influence recovery, muscle function and overall physiological health.
Realistic Expectations
While Ipamorelin has shown promise as a selective growth hormone secretagogue, it cannot replace the lifestyle factors that naturally support healthy growth hormone production.
Optimal endocrine function continues to depend on:
- High-quality sleep
- Regular exercise
- A balanced, protein-rich diet
- Healthy body composition
- Effective stress management
- Good hydration
- Smoking avoidance
- Moderate alcohol consumption
Scientific References
- Raun K, Hansen BS, Johansen NL, et al. — Foundational Ipamorelin Study
Ipamorelin, the First Selective Growth Hormone Secretagogue. European Journal of Endocrinology. 1998;139(5):552–561. This landmark paper first described Ipamorelin and demonstrated its ability to selectively stimulate growth hormone release through the growth hormone secretagogue receptor (GHS-R1a). Importantly, the study showed that Ipamorelin produced minimal stimulation of ACTH and cortisol compared with earlier growth hormone secretagogues, helping establish its reputation as one of the most selective peptides in its class.
Read on PubMed - Gobburu JV, Agersø H, Jusko WJ, Ynddal L.
Pharmacokinetic–Pharmacodynamic Modelling of Ipamorelin, a Growth Hormone-Releasing Peptide, in Human Volunteers. Pharmaceutical Research. 1999;16(9):1412–1416. One of the earliest human studies investigating Ipamorelin. The researchers evaluated its pharmacokinetic and pharmacodynamic profile, demonstrating dose-dependent stimulation of endogenous growth hormone release in healthy volunteers.
Read on PubMed - Davenport AP, Bonner TI, Foord SM, et al.
International Union of Pharmacology. LVI. Ghrelin Receptor: Nomenclature, Distribution and Function. Pharmacological Reviews. 2005. This review explains the biology of the ghrelin (GHS-R1a) receptor, the receptor targeted by Ipamorelin. It describes receptor distribution, signalling pathways and its role in regulating endogenous growth hormone secretion.
Read on PubMed - Johansen PB, Nowak J, Skjaerbaek C, et al.
Ipamorelin, a New Growth Hormone-Releasing Peptide, Induces Longitudinal Bone Growth in Rats. Growth Hormone & IGF Research. 1999;9(2):106–113. This preclinical study investigated the effects of Ipamorelin on bone growth and demonstrated increased longitudinal bone growth following stimulation of endogenous growth hormone secretion.
Read on PubMed - Beck DE, Sweeney WB, McCarter MD, et al.
Prospective, Randomized, Controlled Study of the Ghrelin Mimetic Ipamorelin for the Management of Postoperative Ileus Following Bowel Resection. International Journal of Colorectal Disease. 2014;29(12):1527–1534. A Phase II clinical trial evaluating Ipamorelin in patients recovering from bowel surgery. Although the primary focus was gastrointestinal recovery rather than growth hormone physiology, the study provided valuable human safety and tolerability data.
Read on PubMed - Veldhuis JD, Bowers CY.
Integrating GHS and GHRH Signalling in Growth Hormone Regulation. Endocrine Reviews. This review examines how growth hormone secretagogues such as Ipamorelin work alongside Growth Hormone Releasing Hormone (GHRH) to regulate pulsatile growth hormone secretion. It provides important mechanistic insight into why compounds such as Ipamorelin and CJC-1295 (No DAC) are frequently investigated together.
Read on PubMed - Patel YA, Smith RG.
Ghrelin Receptor Biology and Growth Hormone Secretagogues. Frontiers in Endocrinology. A comprehensive review discussing ghrelin receptor signalling, endogenous growth hormone regulation and the pharmacology of selective growth hormone secretagogues, including Ipamorelin. The paper also explores the therapeutic potential and limitations of this class of compounds.
Read on PubMed
Ipamorelin FAQ's
What is Ipamorelin Peptide?
Ipamorelin is a synthetic growth hormone secretagogue (GHS) designed to stimulate the body's natural release of growth hormone. It works by activating the ghrelin (GHS-R1a) receptor in the pituitary gland, which triggers a physiological pulse of endogenous growth hormone. Unlike recombinant growth hormone, Ipamorelin encourages the body to produce its own growth hormone rather than supplying it directly.
Researchers commonly investigate Ipamorelin for its potential effects on growth hormone secretion, IGF-1 production, body composition, exercise recovery and healthy ageing.
How Much Bacteriostatic Water for 5mg Ipamorelin?
There is no single correct amount of bacteriostatic water to use, as the volume chosen simply determines the final concentration of the reconstituted peptide.
For a 5mg vial of Ipamorelin, many researchers choose to add 3ml of bacteriostatic water, as this provides a convenient concentration for calculating research measurements.
The amount of bacteriostatic water does not change the total quantity of peptide present—it only changes the concentration of the solution after reconstitution.
How Long Does Ipamorelin Take to Work?
Ipamorelin causes a pulse of growth hormone within minutes with a maximum of 30 to 60 minutes. But it takes time for physical results. Within 2 to 4 weeks, you’ll notice initial changes such as deeper sleep, but visible changes in body composition, fat loss and muscle recovery take 8 to 12 weeks of consistent use
Where to Buy Ipamorelin
If you're looking for high-purity research-grade Ipamorelin, Kensington Labs supplies independently tested peptides manufactured to rigorous quality standards.
Every batch is supported by third-party laboratory testing and batch-specific Certificates of Analysis (COAs), allowing researchers to verify product identity and purity before use.
All products supplied by Kensington Labs are intended strictly for laboratory research purposes only and are not intended for human consumption.
How to Inject Ipamorelin
Ipamorelin is commonly investigated using subcutaneous injection in research settings.
For a detailed step-by-step guide covering preparation, injection sites, sterile technique and safe handling procedures, please refer to our guide:
https://kensingtonlabs.co.uk/how-to-inject-peptides/
Always ensure appropriate sterile technique is followed during laboratory handling and preparation.
How Much Ipamorelin Per Day?
There is no regulator-approved human dosing protocol for Ipamorelin, and dosing varies between published research studies.
The example research protocol outlined on this page follows a gradual titration schedule, beginning at 100 mcg daily before progressively increasing to 250 mcg daily over the course of the protocol.
For a complete breakdown of the weekly exposure levels used in this example protocol, please refer to the dosage chart included in the Research Protocol section above.
This protocol is provided for research reference only and should not be interpreted as a recommended human dosing regimen.
